TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38261
Drug: Clobazam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (40 mg daily, increased to 80 mg daily by day 3 if well tolerated)
Study: 31676280
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (CMT)
Study: 28272220
Drug: Sertraline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline + Doxazosin (4mg + 50mg)
Study: 26299324
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h continuous infusion)
Study: 24060577
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with detectable circulating tumor cells (CTCs)
Study: 24060577
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy without detectable circulating tumor cells (CTCs)
Study: 21119518
Drug: Low-flow inhalational
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow inhalational anaesthesia (1 l min(‐1) O2 + 0.5 l min(‐1) N2O + desflurane)
Study: 21119518
Drug: High-flow inhalational
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow inhalational anaesthesia (3 l min(‐1) O2 + 1.5 l min(‐1) N2O + desflurane)
Study: 18069178
Drug: 2% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% w/w minocycline gel (Dentomycin)
Study: 29998359
Drug: Neuromuscular blocker
Normalized name: Neuromuscular blocker product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocker (NM) group
Study: 29998359
Drug: Non-neuromuscular blocker
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-neuromuscular blocker (non-NM) group
Study: 18463891
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride drink with 1 mmol/l sodium concentration
Study: 18463891
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride drink with 31 mmol/l sodium concentration
Study: 18463891
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride drink with 40 mmol/l sodium concentration
Study: 18463891
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride drink with 50 mmol/l sodium concentration
Study: 17138196
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) and postoperative PCA intravenous morphine
Study: 14627850
Drug: Coralline hydroxyapatite
Normalized name: Corallina officinalis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coralline hydroxyapatite implants
Study: 14627850
Drug: High density
Normalized name: High density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High density porous polyethylene (Medpore) implants
Study: 27098822
Drug: Colistin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin plus meropenem combination therapy
Study: 22682898
Drug: Denufosol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denufosol (60 mg via inhalation three times daily)
Study: 20679620
Drug: Vinblastine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (6 mg/m²) during each chemotherapy course followed by weekly vinblastine for a total of 1 year
Study: 17880718
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (analgesics as needed)
Study: 17880718
Drug: Cost effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost effectiveness of corticosteroid injection therapy
Study: 16141015
Drug: Heliox-driven albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-driven albuterol therapy
Study: 7745800
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of 4% lidocaine HCl
Study: 7745800
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of nicardipine HCl + 5 ml of distilled water
Study: 7745800
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of verapamil HCl + 5 ml of distilled water
Study: 7745800
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of diltiazem HCl + 5 ml of distilled water
Study: 2134114
Drug: Buspirone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (initial dose 15 mg, mean final dose 22.2 mg)
Study: 2134114
Drug: Oxazepam (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (initial dose 45 mg, mean final dose 55.8 mg)
Study: 29890542
Drug: Leucine administration
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine administration (25g) with glucose infusion
Study: 29890542
Drug: Control (250ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (250ml water with glucose infusion)
Study: 27259300
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of Tirofiban and Fondaparinux
Study: 21464426
Drug: Interferon β‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1b 250 μg
Study: 21464426
Drug: Interferon β‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1b 500 μg
Study: 9893539
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 1 mg.kg‐1 (T1)
Study: 9893539
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 2 mg.kg‐1 (T2)
Study: 9893539
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine 1 mg.kg‐1 (PE)
Study: 29267375
Drug: Standard versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard versus New Antiepileptic Drugs (SANAD) treatment
Study: 23390177
Drug: Verum stimulation
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum stimulation (Cefaly, STX‐Med., Herstal, Belgium) applied daily for 20 minutes for 3 months
Study: 22005160
Drug: Rapid initiation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid initiation of quetiapine (up to 800 mg/d by Day 4)
Study: 22005160
Drug: Conventional initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional initiation of quetiapine (up to 400 mg/d by Day 5)
Study: 19200399
Drug: Supervised multi-modal
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised multi-modal exercise therapy programme
Study: 19200399
Drug: Individualised manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised manual therapy programme
Study: 19200399
Drug: Both exercise
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both exercise therapy and manual therapy
Study: 15164336
Drug: Egg diet
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg diet (640 mg/d additional dietary cholesterol)
Study: 15164336
Drug: Placebo diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diet (0 mg/d additional dietary cholesterol)
Study: 11240880
Drug: Diclofenac 1-2
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 1-2 mg.kg-1
Study: 11240880
Drug: Acetaminophen 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 22.5 mg.kg-1
Study: 3682574
Drug: reserpin (0.5‐0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: reserpin (0.5‐0.75 mg/day)
Study: 3682574
Drug: dopegyt (750‐1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: dopegyt (750‐1500 mg/day)
Study: 3682574
Drug: clophelin (0.3‐0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: clophelin (0.3‐0.6 mg/day)
Study: 3682574
Drug: anaprilin (80‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: anaprilin (80‐160 mg/day)
Study: 3682574
Drug: hydrochlorothiazide (25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25‐100 mg/day)
Study: 28687830
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions.
Study: 28687830
Drug: Weekly concurrent
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions without cetuximab.
Study: 28687830
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to concurrent chemoradiation.
Study: 25385096
Drug: Primaquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine alone (30 mg base)
Study: 25385096
Drug: Pyronaridine-artesunate alone
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pyronaridine-artesunate alone (540-180 mg)
Study: 23266402
Drug: Nebulized Dornase
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Dornase alfa administered twice daily until extubation, death, or transfer
Study: 23266402
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily until extubation, death, or transfer
Study: 17000366
Drug: D-dimer greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer greater than 4.1 mmol/L
Study: 8682466
Drug: Combined locoregional
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined locoregional immuno-chemotherapy (Group B)
Study: 8682466
Drug: Locoregional chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional chemotherapy (Group A)
Study: 1868748
Drug: Naftifine gel
Normalized name: naftifine Topical Gel
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine gel 1 percent applied twice daily for four weeks
Study: 1868748
Drug: Gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel vehicle applied twice daily for four weeks
Study: 31008751
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 µg/kg
Study: 30985379
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 µg/kg)
Study: 29724499
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl 250 mg TID
Study: 29724499
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl 500 mg TID
Study: 11139861
Drug: Maternity gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternity gel pads
Study: 9132351
Drug: Subcutaneous Redon
Normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Redon drains
Study: 3523240
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin given for five days
Study: 16617220
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention based on cognitive behavioral therapy
Study: 12716076
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (Ca‐A)
Study: 12716076
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor (ACE‐I)
Study: 11066055
Drug: Oral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chemotherapy with trofosfamide (100 mg/m2) and etoposide (25 mg/m2), daily or for 21-day cycles interrupted by 1-week rests, with concurrent standard fractionated radiation (54 grays).
Study: 8840284
Drug: Chronic rEPO
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic rEPO therapy
Study: 8840284
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving rEPO therapy
Study: 1632179
Drug: Succinylcholine (groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (groups F, G)
Study: 1632179
Drug: Lidocaine in
Normalized name: lidocaine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine in combination with atracurium (group D)
Study: 1632179
Drug: Lidocaine in
Normalized name: lidocaine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine in combination with succinylcholine (group G)
Study: 28976210
Drug: Vigna nakashimae
Normalized name: Vigna radiata extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigna nakashimae extract (1 g thrice daily)
Study: 28976210
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (control group)
Study: 24226568
Drug: Clobetasol propionate,
Normalized name: Clobetasol Propionate, 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol propionate, 0.05% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Study: 24226568
Drug: Hydrocortisone, 1%
Normalized name: MD Hydrocortisone, 1% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone, 1% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Study: 22830016
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg/d and Tretinoin 10 mg/BID for six months
Study: 22830016
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Pioglitazone and Tretinoin)
Study: 19128256
Drug: Biatain Ibu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biatain Ibu Nonadhesive (foam dressing with ibuprofen)
Study: 19128256
Drug: Biatain Non-Adhesive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biatain Non-Adhesive (foam dressing without ibuprofen)
Study: 16648092
Drug: Reflexology treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatments
Study: 14665498
Drug: Guaifenesin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaifenesin (400 mg)
Study: 11035667
Drug: European Commission
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Commission for Steel and Coal questionnaire and spirometry with bronchodilator test
Study: 8767350
Drug: Isradipine monotherapy
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine monotherapy (n = 32)
Study: 8767350
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Isradipine + metoprolol/enalapril) (n = 11)
Study: 8767350
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single administration of isradipine 5 mg for responsiveness testing)
Study: 1623868
Drug: Prehospital thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital thrombolytic treatment with anistreplase
Study: 1623868
Drug: In-hospital thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital thrombolytic treatment with anistreplase
Study: 6435272
Drug: Cefamandole nafate
Normalized name: Cefamandole Nafate
DrugBank: Cefamandole nafate (DB14725)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefamandole nafate 2 gm administered intravenously preoperatively and 6 hours postoperatively in four doses
Study: 6435272
Drug: Cefamandole nafate
Normalized name: Cefamandole Nafate
DrugBank: Cefamandole nafate (DB14725)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefamandole nafate 0.4% solution: 250 ml to irrigate the abdominal wound on opening, 500 ml to irrigate the peritoneal cavity, and 250 ml to irrigate the wound on closing
Study: 6435272
Drug: Systemic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic plus topical administrations as in Nos. 1 and 2
Study: 31568000
Drug: Adjuvant moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant moxibustion therapy with usual care for 12 weeks (24 sessions)
Study: 31568000
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (acetaminophen on demand and self-directed exercise education)
Study: 31568000
Drug: Adjuvant moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant moxibustion therapy
Study: 22146409
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a three times a week
Study: 22146409
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a once a week
Study: 12003177
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) during structured treatment interruptions (STI) of HAART
Study: 12003177
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruptions (STI) of HAART
Study: 24206639
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation treatment (weekly group-based for 12 weeks)
Study: 19517247
Drug: Memantine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine at a dose of 20 mg/day
Study: 12469544
Drug: Multicomponent medication
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent medication adherence intervention (behavioral strategies, simplified patient information, social support, cognitive‐behavioral therapy, nursing)
Study: 12469544
Drug: Multicomponent medication
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent medication adherence intervention
Study: 9802635
Drug: Oral tetravalent
Normalized name: rotavirus vacc, live oral tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tetravalent rotavirus vaccine (RV‐TV)
Study: 8575610
Drug: Fundus III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fundus III oral liquid (10ml/time P.O. t.i.d. for 1 month)
Study: 2197910
Drug: Inhaled pentamidine
Normalized name: pentamidine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled pentamidine (8 mg/kg body weight)
Study: 2197910
Drug: Intravenous pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pentamidine (4 mg/kg body weight)
Study: 2197910
Drug: Inhaled pentamidine
Normalized name: pentamidine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled pentamidine
Study: 92830
Drug: Neutron treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron treatment (full course of 16 Gy)
Study: 92830
Drug: Neutron treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron treatment (reduced doses of 10 to 14 Gy)
Study: 28009692
Drug: 10,600 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,600 nm ablative fractional carbon dioxide (CO2) laser treatment (3 sessions)
Study: 24382970
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell treatment
Study: 8807183
Drug: PCORA (Patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCORA (Patient Controlled Oral Analgesia)
Study: 8807183
Drug: CPPT (Customarily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPPT (Customarily Prescribed Pain Therapy)
Study: 1679661
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (20 mg)
Study: 1679661
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (celiprolol and nifedipine)
Study: 1679661
Drug: Intravenous celiprolol
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous celiprolol (8 mg) during exercise
Study: 1679661
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (20 mg) during exercise
Study: 1679661
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy during exercise
Study: 30514115
Drug: Group exercises
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercises (strength and aerobic exercises) performed twice a week for 24 weeks
Study: 26905112
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy (5 fluorouracil, adriamycin, and cyclophosphamide) followed by modified radical mastectomy
Study: 26905112
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after modified radical mastectomy
Study: 24942155
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose recombinant human follicle-stimulating hormone (r-hFSH) protocol (starting daily dose: 75 IU, dose increase on Day 14)
Study: 24942155
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human follicle-stimulating hormone (r-hFSH) protocol (starting daily dose: 75 IU, dose increase on Day 7)
Study: 12039482
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) streptokinase